Dupilumab for the treatment of immune checkpoint blockers' induced pruritus

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1475-e1476. doi: 10.1111/jdv.19369. Epub 2023 Jul 27.

Authors

Evdoxia Panou¹, Flora Stavridi², Christos Nikolaou³, Alexander Stratigos¹, Vasiliki Nikolaou¹

Affiliations

¹ 1st Dermatology Department, 'Andreas Syngros' Hospital for Skin Diseases, National & Kapodestrian University of Athens, Athens, Greece.
² 4th Oncology Department, Hygeia Hospital, Athens, Greece.
³ Oncology Department, Queen's Hospital, London, UK.

PMID: 37471503
DOI: 10.1111/jdv.19369

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Double-Blind Method
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Pruritus / chemically induced
Pruritus / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Immune Checkpoint Inhibitors
Antibodies, Monoclonal, Humanized